TGA wants to ban compounded semaglutide because of safety concerns
Compounding the diabetes drug could be off the table under the watchdog's proposals.
The TGA wants to ban pharmacists from compounding their own versions of semaglutide based on safety concerns about the “commercial scale” of operations.
The watchdog has proposed removing all medicines containing GLP-1 receptor agonist analogues (GLP-1 RAs) from the legal provisions that let pharmacists compound medications without a drug manufacturing licence.
